Skip to content

UG200 / UG200 Ultra — Ultima Genomics

Ultima's wafer-based single-end SBS platform at production scale — 162 Tb/wk ceiling and Q60 ppmSeq duplex-equivalent reads, optimized for cohort-scale exome and WGS.

At a glance

  • Vendor / launch date / availability: Ultima Genomics; presented and shipping at AGBT 2026 per Vilella Substack Part 1.
  • Chemistry / modality: Single-end sequencing-by-synthesis on circular silicon wafers using isothermal amplification; paired-end ("Solaris 2.0") on the 2026 roadmap per Vilella Substack Part 1.
  • Throughput (PR): Up to 162 Tb/week maximum; 60 wafers/week throughput on UG200 Ultra; ~1,350 genome-equivalents/week (Ultra) per Vilella Substack Part 1 (vendor PR — no independent benchmark).
  • Read length: Up to ~300 bp single-end; paired-end on the Solaris 2.0 roadmap per Vilella Substack Part 1.
  • Accuracy (PR): Q60 ppmSeq duplex-equivalent per Vilella Substack Part 1 (vendor PR — no independent benchmark).
  • List price / cost-per-genome: $850k (UG200 / single wafer) and $1.25M (UG200 Ultra) per Vilella Substack Part 1.

What's new vs prior generation

UG200 follows the UG100 wafer-sequencer, doubling effective wafer throughput and introducing the UG200 Ultra tier (multi-wafer, ~1,350 genomes/week). Ppm­Seq accuracy moves from ~Q40 duplex-equivalent on the prior generation to Q60 on UG200, narrowing the duplex-accuracy gap with PacBio HiFi and Roche SBX while preserving the single-end / cohort-scale economics that have been Ultima's pitch since launch. The Solaris 2.0 paired-end roadmap, if it ships, would close the historical gap vs Illumina/Element for variant callers tuned to PE inserts.

Headline benchmarks

  • 162 Tb/wk ceiling and ~1,350 genome-equivalents/week on UG200 Ultra (vendor PR — no independent benchmark) — Vilella Substack Part 1.
  • Q60 ppmSeq duplex-equivalent across the production wafer (vendor PR — no independent benchmark) — Vilella Substack Part 1.

Reception / competitive context

UG200 is the throughput ceiling of the AGBT 2026 short-read lineup; Element VITARI and Complete DNBSEQ-T7+ compete on price ($100 vs Ultima's higher capital cost) while Ultima retains the per-week genome-count advantage. Roche Axelios's $150 genome is an order of magnitude lower in instrument cost ($750k) but ships later (summer 2026). GenomeWeb's "battle royale" recap and the GEN AGBT recap both put Ultima in the "incumbent at cohort scale" position, with Element as the principal challenger.

  • Downstream Bioconductor tools: short-read aligners + variant callers; methylKit for any duplex methylation work; cohort-scale workflows in [GBCC 2025 spatialLIBD-adjacent population-genomics talks].
  • Competitive context in this AGBT lineup: Element VITARI (price challenger), Roche Axelios 1 (cost-per-genome floor), Complete DNBSEQ-T7+ ($100 genome twin).
  • AACR 2026 tie-in: AACR posters tagged "Ultima" / "single-end" + cancer cohort scale are the natural first wave of UG200-era data.

Sources